Fusobacterium Nucleatum

A Gram-negative obligate anaerobe that has emerged as a major pathogen in colorectal cancer (CRC) and inflammatory bowel disease. F. nucleatum is significantly enriched in CRC tissue and tumors compared to healthy mucosa, making it one of the strongest microbe-cancer associations in the gut. Its abundance correlates with poorer prognosis, and its virulence depends critically on iron and manganese acquisition systems that allow it to compete in the inflamed, metal-rich colonic environment.

Iron Acquisition and Metalloprotein Dependence

Hemolytic and Hemin-Dependent Peroxidase

  • F. nucleatum possesses robust hemolytic activity and expresses hemin-dependent peroxidases that require iron prosthetic groups.
  • Specializes in heme acquisition from lysed red blood cells and hemoglobin, particularly abundant in inflamed tissue where barrier breakdown releases luminal blood.
  • Iron (Fe²⁺/Fe³⁺) is essential for cytochrome c oxidase, catalases, and peroxidases — core components of the anaerobic electron transport chain.
  • Maintains multiple iron-uptake systems including transferrin-binding capacity and siderophore-mediated iron scavenging.

Manganese Requirement

  • Manganese (Mn²⁺) is critical for F. nucleatum superoxide dismutase (Mn-SOD), protecting against oxidative stress in the inflammatory colonic microenvironment.
  • Elevated colonic manganese levels (part of the CRC metallomic signature) favor Fusobacterium proliferation.

FadA Adhesin: Virulence and Epithelial Invasion

The FadA Effector

  • The FadA adhesin is a fibrils-associated adhesin that mediates bacterial adherence to intestinal epithelial cells and invasive interactions.
  • FadA binds to E-cadherin on epithelial cells, activating beta-catenin/Wnt signaling and promoting epithelial proliferation.
  • This signaling is pro-tumorigenic: constant FadA-E-cadherin engagement drives persistent Wnt activation, dysregulating cell growth and differentiation.
  • FadA also recruits and activates immune cells, sustaining chronic inflammation.

Iron Context

  • FadA expression and secretion are upregulated under iron-rich conditions, making the adhesin's virulence responsive to local iron availability.

Biofilm Formation and Ecological Dominance

  • F. nucleatum is a prolific biofilm former, particularly in CRC and IBD lesions. Biofilm architecture provides:
  • Protected microenvironments where FadA-producing cells can persist despite host immunity.
  • Reduced oxygen availability (beneficial for obligate anaerobes).
  • Metabolic cross-feeding and division of labor (some cells specialize in iron scavenging, others in virulence).
  • Reduced antibiotic and bile salt penetration.
  • Biofilms composed of F. nucleatum and porphyromonas gingivalis or prevotella copri are particularly resistant to clearance.

Disease Associations

Colorectal Cancer (CRC)

  • Mechanistic link: Iron-rich inflamed tissue selects for Fusobacterium. High iron availability sustains FadA expression, driving E-cadherin cleavage and Wnt activation [1].
  • F. nucleatum DNA is detectable in tumors, with CFU counts correlating with worse clinical outcomes [2] [3].
  • CRC microbiome signatures consistently show elevated Fusobacterium alongside iron and manganese elevation [4] [5].
  • FadA-mediated epithelial transformation is synergistic with dysplasia: the combination of disrupted tight junctions and oncogenic signaling accelerates malignant progression [6] [7].
  • FMT and dietary interventions that deplete Fusobacterium are under active investigation as adjuncts to CRC chemo- and immunotherapy [8] [9].

Other Gastrointestinal and Gynecologic Cancers

  • Pancreatic cancer: F. nucleatum is detected in pancreatic tumor microbiomes and contributes to a pro-tumorigenic dysbiosis [10].
  • Esophageal disease and upper-GI carcinogenesis: Fusobacterium is enriched in Type II (Gram-negative, inflammatory) esophageal microbiome signatures linked to reflux, Barrett's, and carcinogenesis [11] [12] [13].

Periodontitis and Systemic Disease

  • F. nucleatum is a core oral pathobiont in periodontitis and a bridging species in oral polymicrobial biofilms; its oral-to-gut and oral-to-vascular translocation links periodontal disease to systemic inflammation [14] [15] [16].
  • Oral Fusobacterium signatures are also altered in multiple sclerosis oral microbiome studies [17] [18].

Inflammatory Bowel Disease (IBD)

  • Enriched in both Crohn's disease and ulcerative colitis, particularly in inflamed segments.
  • Sustained by the iron-rich environment of bleeding intestinal mucosa.
  • Perpetuates inflammation through FadA-driven immune activation and epithelial damage.

Metabolic Features

  • Fermentative metabolism producing butyrate and other short-chain fatty acids, but does not produce levels sufficient to be anti-inflammatory.
  • Produces collagenase and other tissue-degrading proteases, compounding barrier disruption in IBD.
  • Lacks robust SCFA-mediated immune tolerance mechanisms seen in faecalibacterium prausnitzii or roseburia.

Ecological Context

  • Thrives in oxygen-limited environments with elevated iron (inflamed, hemorrhagic tissue).
  • Outcompetes obligate anaerobes that lack robust iron acquisition (e.g., faecalibacterium prausnitzii, roseburia).
  • Often co-enriched with other iron-dependent pathobionts like bacteroides vulgatus and gram-positive iron-scavenging taxa.
  • Depleted in healthy gut; restored rapidly when inflammation and barrier breakdown create favorable conditions.

Clinical Significance

  • Considered a CRC-predictive biomarker: presence of F. nucleatum in a healthy-appearing individual warrants further CRC screening.
  • Abundance in biopsies correlates with tumor stage and patient prognosis independent of other variables.
  • F. nucleatum presence may influence response to immunotherapy in CRC, as the organism's presence suppresses anti-tumor immunity.

Connections

  • iron — essential cofactor for heme-dependent peroxidases and E-transport chain; high-iron conditions drive FadA virulence
  • manganese — Mn-SOD critical for survival in oxidative inflammatory environment
  • colorectal cancer — major CRC pathogen, FadA-E-cadherin signaling drives tumorigenesis
  • inflammatory bowel disease — enriched in IBD lesions, perpetuates bleeding and iron-driven dysbiosis
  • — FadA target; E-cadherin cleavage activates oncogenic Wnt signaling
  • barrier-disruption — produces collagenase and matrix-degrading proteases
  • biofilm — prolific biofilm former; resistant to clearance in tissue lesions
  • metal carcinogenesis — illustrative example of how metal elevation (iron, Mn) selects for carcinogenic pathobiont

References (23)

  1. Lan Zhao, William C. Cho, Mark R. Nicolls (2021). Colorectal cancer-associated microbiome patterns and signatures. Frontiers in Genetics. doi:10.3389/fgene.2021.787176
  2. Thomas AM, Jesus EC, Lopes A et al. (2016). Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2016.00179
  3. Yu L, Zhao G, Wang L et al. (2022). A Systematic Review of Microbial Markers for Risk Prediction of Colorectal Neoplasia. British Journal of Cancer. doi:10.1038/s41416-022-01740-7
  4. Shaomin Zou, Chao Yang, Jieping Zhang et al. (2024). Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer. Journal of Translational Medicine. doi:10.1186/s12967-024-04984-4
  5. Youwen Qin, Xin Tong, Wei-Jian Mei et al. (2024). Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer. Nature Communications. doi:10.1038/s41467-024-47523-x
  6. Wu Y, Jiao N, Zhu R et al. (2021). Identification of Microbial Markers across Populations in Early Detection of Colorectal Cancer. Nature Communications. doi:10.1038/s41467-021-23265-y
  7. Saito K, Koido S, Odamaki T et al. (2019). Metagenomic Analyses of the Gut Microbiota Associated with Colorectal Adenoma. PLOS ONE. doi:10.1371/journal.pone.0212406
  8. Hui Xu, Chenxi Cao, Yuqing Ren et al. (2022). Antitumor Effects of Fecal Microbiota Transplantation: Implications for Microbiome Modulation in Cancer Treatment. Frontiers in Immunology
  9. Lena Van Dingenen, Charlotte Segers, Shari Wouters et al. (2023). Dissecting the Role of the Gut Microbiome and Fecal Microbiota Transplantation in Radio- and Immunotherapy Treatment of Colorectal Cancer. Frontiers in Cellular and Infection Microbiology
  10. Tao Zhang, Guangqi Gao, Hafiz Arbab Sakandar et al. (2022). Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target. Frontiers in Nutrition. doi:10.3389/fnut.2022.814269
  11. Alageel AA, Alomran DA, Alharbi HB et al. (2025). Alageel 2025 — Examining the Microbiome Composition in Patients with Gastroesophageal Reflux Disease: A Systematic Review. TPM (The Primary Care Companion for CNS Disorders)
  12. Deshpande NP, Riordan SM, Castano-Rodriguez N et al. (2018). Deshpande 2018 — Esophageal Microbiome Signatures and Host Genetics. Microbiome. doi:10.1186/s40168-018-0611-4
  13. Catala-Valentin AR, Mikhail S, Bernard JN et al. (2021). Corruption of Bacterial-Host Homeostasis as a Potential Risk Factor and Biomarker for Upper Gastrointestinal Carcinogenesis. Journal of Gastroenterology and Hepatobiliary Medicine
  14. Max Foroughi, Keykavous Parang (2026). Periodontal Biomarkers in Cardiovascular Disease: Mechanisms, Diagnostics, and Clinical Implications. Infection. doi:10.1007/s15010-026-02778-y
  15. Various (2021). Periodontitis and T2D — Endogenous and Microbial Biomarkers for Periodontitis and Type 2 Diabetes Mellitus. Various
  16. Boyu Tang, Caixia Yan, Xin Shen et al. (2022). Tang 2022 — The Bidirectional Biological Interplay between Microbiome and Viruses in Periodontitis and Type-2 Diabetes Mellitus. Frontiers in Immunology. doi:10.3389/fimmu.2022.885029
  17. Zangeneh Z, Abdi-Ali A, Khamooshian K et al. (2021). Bacterial Variation in the Oral Microbiota in Multiple Sclerosis Patients. PLoS ONE. doi:10.1371/journal.pone.0260384
  18. Léo Boussamet, Emmanuel Montassier, Camille Mathé et al. (2024). Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study. Scientific Reports. doi:10.1038/s41598-024-57949-4
  19. Xiaopeng Li, Jiahui Feng, Zhanggui Wang et al. (2023). Features of combined gut bacteria and fungi from a Chinese cohort of colorectal cancer, colorectal adenoma, and post-operative patients. Frontiers in Microbiology. doi:10.3389/fmicb.2023.1236583
  20. Rachel L. Fitzjerrells, Leeann Aguilar Meza, Meeta Yadav et al. (2025). Multiple Sclerosis Patients Exhibit Oral Dysbiosis with Decreased Early Colonizers and Lower Hypotaurine Level. npj Biofilms and Microbiomes. doi:10.1038/s41522-025-00787-7
  21. Kudra A, Muszynski D, Sobocki BK et al. (2023). Insights into Oral Microbiome and Colorectal Cancer - On the Way of Searching New Perspectives. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2023.1159822
  22. Paloma Gonzalez-Sanchez, Gina M. DeNicola (2021). The microbiome(s) and cancer: know thy neighbor(s). Journal of Pathology. doi:10.1002/path.5661
  23. Asangba AE, Chen J, Goergen KM et al. (2023). Asangba 2023 — Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response. Scientific Reports. doi:10.1038/s41598-023-27555-x

Related Articles